The FDA has delayed its decision to approve the weight loss drug, Qnexa. The target date has been pushed back to July 17 to consider a new drug safety plan submitted by the manufacturer, Vivus. Previously the agency was scheduled to make a decision by April 17. Vivus stated the three-month extension is standard when companies submit additional risk management information for a drug.
We are now completely out of the Bontril 35mg tablets and 105mg capsules. If you were using these products, please contact us to discuss the generic alternatives.